胃肠胰神经内分泌肿瘤的PET/CT与PET/MRI
本文综述了分子影像在胃肠胰神经内分泌肿瘤(GEP-NENs)管理中的应用趋势、陷阱与进展。生长抑素受体(SSTR)PET已成为评估NENs的参考标准,尤其在肽受体放射性核素治疗(PRRT)资格判定中至关重要;SSTR PET/MRI联合肝特异性对比剂有潜力实现一站式多参数评估;18F-FDG是SSTR的互补示踪剂,尤其在高分级NENs中。
要点
- SSTR PET是评估NENs的参考标准,在PRRT资格判定中尤为关键。
- SSTR PET/MRI联合肝特异性对比剂有望一站式多参数评估GEP-NENs。
- 18F-FDG是SSTR的互补示踪剂,尤其适用于高分级NENs。
核心结论
- SSTR PET已成为评估NENs的参考标准,在PRRT资格判定中尤为关键;SSTR PET/MRI联合肝特异性对比剂有潜力实现一站式多参数评估;18F-FDG是SSTR的互补示踪剂,尤其适用于高分级NENs;定量评估及其在PRRT和联合治疗疗效评估中的作用是活跃的研究领域,新型示踪剂有潜力克服现有局限。
研究设计与样本
- 综述性文章,旨在概述GEP-NENs分子影像的当前趋势、陷阱与最新进展;原文未报告系统检索范围与纳入文献数量。
临床应用与阅片要点
- SSTR PET是评估NENs的参考标准,在PRRT资格判定中尤为关键。
- SSTR PET/MRI联合肝特异性对比剂有潜力实现GEP-NENs的一站式多参数评估。
- 18F-FDG可作为SSTR的互补示踪剂,尤其在高分级NENs中。
局限性
- 分子影像研究的定量评估及其在PRRT和联合治疗疗效评估中的作用仍存在知识空白,是活跃的研究领域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Advanced molecular imaging has come to play an integral role in the management of gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). Somatostatin receptor (SSTR) PET has now emerged as the reference standard for the evaluation of NENs and is particularly critical in the context of peptide receptor radionuclide therapy (PRRT) eligibility. SSTR PET/MRI with liver-specific contrast agent has a strong potential for one-stop-shop multiparametric evaluation of GEP-NENs. 18F-FDG is a complementary radiotracer to SSTR, especially in the context of high-grade neuroendocrine neoplasms. Knowledge gaps in quantitative evaluation of molecular imaging studies and their role in assessment of response to PRRT and combination therapies are active research areas. Novel radiotracers have the potential to overcome existing limitations in the molecular imaging of GEP-NENs. The purpose of this article is to provide an overview of the current trends, pitfalls, and recent advancements of molecular imaging for GEP-NENs.
引用
- Rajamohan, Khasawneh, Singh, et al. PET/CT and PET/MRI in neuroendocrine neoplasms. Abdom Radiol (NY). 2022. PMID: 35426497. doi:10.1007/s00261-022-03516-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。